Open AccessHuman Insulin (Entuzity KwikPen)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.169
Subject(s) - reimbursement , glycemic , human insulin , insulin , medicine , diabetes mellitus , drug , subcutaneous injection , drug class , intensive care medicine , pharmacology , business , endocrinology , political science , law , health care
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses human biosynthetic insulin (Entuzity KwikPen), 500 units/mL subcutaneous insulin injection, human biosynthetic, solution for injection
Indication: Entuzity is indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day